empty
 
 
bg
Търсене
Подкрепа
Незабавно отваряне на акаунт
Платформа за търговия
Депозит / Теглене
Търсене
За начинаещи За търговци За партньори Вземете си почивка За ИнстаФорекс
bg
#DHR Обратно към списъка с инструменти #DXCM

Конвентор на валута

Dynavax Technologies Corporation
10.89 USD
09 Dec 2025 22:59
Ценова промяна (% chg)
$-0.02
(-0.18%)
Предишно затваряне
Предишно затваряне

Затваряща цена, предишен ден.
$10.96
Отваряне
Отваряне

Цена на отваряне.
$10.93
Дневен връх
Дневен връх

Най-високата цена през последния търговски ден.
$11.12
Дневно дъно
Дневно дъно

Най-ниската цена през последния ден за търговия
$10.85
52-седмичен връх
52-седмичен връх

Връх на ценовия диапазон за последните 52 седмици
$11.28
52-седмично дъно
52-седмично дъно

Дъно на ценовия диапазон за последните 52 седмици
$10.62
Свалете архива
Buy
10.89
Sell
10.89
Open the chart in full screen view
Buy
10.89
Sell
10.89
Свалете архива
Open the chart in full screen view

Dynavax Technologies Corporation. About company

Dynavax Technologies Corporation is a biopharmaceutical company whose core business is the development and production of vaccines.

The company’s main product is a hepatitis B drug. The company also produces vaccines against coronavirus, influenza, plague, and other infectious diseases.

In addition, the company is mainly focused on the production of adjuvants. These substances help vaccines to be better absorbed by the body.

Currently, Dynavax has a market capitalization of $1.37 billion. Last year, the company posted revenues of $438.24 million and a net income of $76.71 million.

Dynavax Technologies Corporation’s shares and what affects their price

Dynavax shares have been trading on the NASDAQ exchange under the DVAX ticker since 2004. The initial price per share stood at $7.50.

Currently, the company’s shares are trading between $10 and $12. During the year, the share price was hovering between $7 and $22. At the same time, the company does not pay dividends to its shareholders.

What to pay attention to when trading the company’s shares:

  • Long-term growth prospects are driven by a large number of innovative developments;
  • The target price for the stock is several times higher than the current one, ranging between $45.5 and $48, according to forecasts;
  • Adjuvant technology is an advantage for the company since these additional substances significantly enhance the effect of the vaccines.

Не можете да говорите точно сега?
Задайте въпроса си в чат.